Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
Acromegaly (excessive bone growth), causing thickening of the jaw, hands, and feet
It was originally developed to treat growth hormone deficiency and muscle wasting in clinical settings but has since become widely used in the athletic and bodybuilding world for its performance and recovery-enhancing effects
Some individuals also report using microdoses for appetite modulation without seeking the substantial weight loss associated with higher doses, or as a gentler introduction to the medication before escalating to standard doses